www.synthego.com Open in urlscan Pro
52.27.71.54  Public Scan

Form analysis
0 forms found in the DOM

Text Content

You need to enable JavaScript to run this app.
Now Available Engineered Cell Libraries - The biggest development in CRISPR
screening is here! Join Us We're Hiring! Positions are Open Across All Teams and
All Levels Just Released Design and Order Custom Libraries With Our Easy-to-Use
Tool ICE Updates Improved CRISPR Analysis of Multi-Guide Deletions and Knock-In
Edits
Company
 * Platforms
   Overview
   Halo
   Eclipse

 * Company
   About
   Quality
   Newsroom
   Careers
   Partnerships
   Global Distributors
   Contact

Support
 * Help Center
   Ordering
   Product Info
   Analyzing Results
   Troubleshooting
   Tips and Tricks
   Help Center

 * Get in Touch
   Contact

Order
 * Edited Cells
   Knockout Pool
   Knockout Clone

 * Screening
   Custom Library

 * DIY CRISPR
   Synthetic sgRNA
   Knockout Kit
   Cas9 Nuclease

--------------------------------------------------------------------------------

Subscribe
Cart
Your Orders
Account
Sign In

Products Workflows Learn
Schedule a Consultation Contact Sales

--------------------------------------------------------------------------------

Read the Announcement


ACCELERATING THE FIELD OF CRISPR-BASED MEDICINES FROM EARLY-PHASE RESEARCH TO
THE CLINIC

Synthego raises $200 million to expand both the capacity and capabilities of its
Halo and Eclipse Platforms and accelerate the creation of a cell and gene
therapy discovery and development ecosystem.
Discover the Halo Platform  Discover the Eclipse Platform  Join Us  
CRISPR Workflows


PROGRESS SEAMLESSLY THROUGH GENOME ENGINEERING APPLICATIONS.


DRUG DISCOVERY

Precision genome engineering with CRISPR can be used to accelerate and optimize
your drug discovery research journey, from basic research through preclinical
development.

Learn More



CELL & GENE THERAPY

Cell and gene therapies leveraging genome editing are rapidly overcoming many of
the challenges associated with traditional cell therapies. CRISPR is playing a
key role in precise, site-specific, and multiplex editing of cell and gene
therapies.

Learn More

COVID-19


ENABLING COVID-19 RESEARCH

We’re here to support your research. Stay up-to-date with the latest COVID-19
information, resources, publications, and collaboration tools.
Explore the Latest  
Screening Insights


OVER 90% OF DRUG CANDIDATES FAIL TO OBTAIN FDA APPROVAL

Make sure your target is one of the lucky ones
Screening Method


RNAI 
VS. CRISPR

Transiently knocking down a gene versus permanently knocking out a gene can
affect your results.
Library Format


POOLED VS. ARRAYED

Whether you mix or separate your guides before screening can dictate what assay
you can perform.
Guide Packaging


LENTIVIRUS VS. RNP

How guide RNAs are packaged for delivery into cells is just as important as the
sequence itself.
Products


ADVANCED GENOME ENGINEERING, ACCESSIBLE TO ALL.


ENGINEERED CELLS

Unprecedented access to CRISPR genome engineering. Your edit, your cell with
guaranteed results.

See Engineered Cell Products



CRISPREVOLUTION

Synthego offers access to an ecosystem of synthetic RNA solutions for CRISPR
genome engineering.

See CRISPRevolution Products



BIOINFORMATICS TOOLS

Design top-scoring guide RNAs for gene knockout and perform rapid accurate
analysis of Sanger sequences.

Use Our Free Bioinformatics Tools

Guided Edit


NOT SURE WHERE TO START?

Guided Edit helps you navigate a clear-cut decision tree so you arrive at the
best solution for your CRISPR editing goal.
Try Guided Edit  
Learn

GET STARTED WITH CRISPR

KEEP UP WITH THE LATEST

BROWSE PEERS' RESEARCH

SUCCEED IN EDITING

EXPLORE MADE-TO-ORDER OPTIONS

 * Ease into the field of genome engineering with our CRISPR 101 ebook.
 * Brush up on basics with our Everything You Need to Know About CRISPR guide.
 * Learn about genome engineering and its applications in our essential guide.
 * Take a deep dive into CRISPR with our collection of CRISPR resources.

 * Don't miss out on news with our CRISPR news sources page.
 * Subscribe to The Bench blog and get alerts of new CRISPR resources in your
   inbox
 * Tune in to CRISPR Cuts podcast for exciting interviews with genome
   engineering experts
 * Survey trends in the drug discovery sector with our Benchmark Report, Vol.
   02.

 * Peruse our list of Synthego-cited publications across diverse application
   areas
 * See what our customers are saying about our products on our testimonials page
 * Explore the featured research of CRISPR researchers on our customers page
 * Download our customer case study to learn how researchers are using arrayed
   CRISPR libraries

 * Check out our tips and tricks for best results in knock-in experiments.
 * Leverage our comprehensive guide on how to use CRISPR to solve any queries.
 * Get started on the right foot with our how to perform successful experiments
   ebook.
 * Build bigger experiments by expanding your CRISPR research to multiple gene
   models.

 * Calculate your savings when you outsource CRISPR using our CRISPR Calculator.
 * Find out where Synthego has an advantage over other CRISPR editing companies.
 * Make an informed choice between ready-to-use Engineered Cells and DIY CRISPR.
 * Understand the differences between CRISPR knockouts in pool and clone
   formats.

Cited Publications


YOU’LL FIND SYNTHEGO PRODUCTS IN HUNDREDS OF PUBLICATIONS.

LatestFeaturedDisease Modeling/ Research + CancerScreening LibrariesNeuroscience
Metabolic engineering, Mar 2022

MULTIPLEX GENOME EDITING OF MAMMALIAN CELLS FOR PRODUCING RECOMBINANT HEPARIN.

Thacker BE et al. Heparin is an essential anticoagulant used for treating and
preventing thrombosis. However, the complexity of heparin has hindered the
development of a recombinant source, making its supply dependent on a vulnerable
animal population. In nature, heparin is produced exclusively in mast cells,
which a

SYNTHETIC SGRNA

CRISPR DESIGN TOOL

DRUG DISCOVERY, BIOENGINEERING

CRISPR METHODS

Biochemistry and biophysics reports, Mar 2022

CRISPR/CAS9 DISRUPTION OF EPCAM EXON 2 RESULTS IN CELL-SURFACE EXPRESSION OF A
TRUNCATED PROTEIN TARGETED BY AN EPCAM SPECIFIC T CELL ENGAGER.

Bagheri A et al. CRISPR/Cas9 gene-editing technology allows researchers to study
protein function by specifically introducing double-stranded breaks in the gene
of interest then analyze its subsequent loss in sensitive biological assays. To
help characterize one of a series of highly potent, conditionally active, T

Molecular biology of the cell, Mar 2022

PANNEXIN 2 IS EXPRESSED IN MURINE SKIN AND PROMOTES UVB-INDUCED APOPTOSIS OF
KERATINOCYTES.

Sanchez-Pupo RE et al. Pannexins (PANX) are a family of three channel-forming
membrane glycoproteins expressed in the skin. Previous studies have focused on
the role of PANX1 and PANX3 in the regulation of cellular functions in skin
cells while PANX2, the largest member of this protein family, has not been
investigated. I

SYNTHETIC SGRNA

GENE FUNCTION

FUNDAMENTAL BIOLOGY

Toxicology and applied pharmacology, Feb 2022

A RATIONAL APPROACH TO ASSESS OFF-TARGET REACTIVITY OF A DUAL-SIGNAL INTEGRATOR
FOR T CELL THERAPY.

Wang X et al. Cell therapy is an emerging therapeutic modality with the power to
exploit new cancer targets and potentially achieve positive outcomes for
patients with few other options. Like all synthetic treatments, cell therapy has
the risk of toxicity via unpredicted off-target behavior. We describe an empiri

SYNTHETIC SGRNA

DRUG DISCOVERY

CANCER, OTHER METHODS

medRxiv : the preprint server for health sciences, Feb 2022

LIMITED CROSS-VARIANT IMMUNITY AFTER INFECTION WITH THE SARS-COV-2 OMICRON
VARIANT WITHOUT VACCINATION.

Suryawanshi RK et al. SARS-CoV-2 Delta and Omicron strains are the most globally
relevant variants of concern (VOCs). While individuals infected with Delta are
at risk to develop severe lung disease 1 , Omicron infection causes less severe
disease, mostly upper respiratory symptoms 2,3 . The question arises whether
rampa

CRISPR DESIGN TOOL

OTHER

AGRICULTURE/PLANTS

Cell stem cell, Feb 2022

TRAF6 FUNCTIONS AS A TUMOR SUPPRESSOR IN MYELOID MALIGNANCIES BY DIRECTLY
TARGETING MYC ONCOGENIC ACTIVITY.

Muto T et al. Clonal hematopoiesis (CH) is an aging-associated condition
characterized by the clonal outgrowth of pre-leukemic cells that acquire
specific mutations. Although individuals with CH are healthy, they are at an
increased risk of developing myeloid malignancies, suggesting that additional
alterations a

SYNTHETIC SGRNA

DISEASE MODELING/ RESEARCH

CANCER, FUNDAMENTAL BIOLOGY

Cell reports, Feb 2022

FAT3 ACTS THROUGH INDEPENDENT CYTOSKELETAL EFFECTORS TO COORDINATE ASYMMETRIC
CELL BEHAVIORS DURING POLARIZED CIRCUIT ASSEMBLY.

Avilés EC et al. The polarized flow of information through neural circuits
depends on the orderly arrangement of neurons, their processes, and their
synapses. This polarity emerges sequentially in development, starting with the
directed migration of neuronal precursors, which subsequently elaborate neurites
that for

SYNTHETIC SGRNA

GENE FUNCTION

NEUROSCIENCE, FUNDAMENTAL BIOLOGY

Plant biotechnology journal, Feb 2022

STRONG AND TUNABLE ANTI-CRISPR/CAS ACTIVITIES IN PLANTS.

Calvache C et al. CRISPR/Cas has revolutionized genome engineering in plants.
However, the use of anti-CRISPR proteins as tools to prevent CRISPR/Cas-mediated
gene editing and gene activation in plants has not been explored yet. This study
describes the characterization of two anti-CRISPR proteins, AcrIIA4 and AcrVA1

ICE CRISPR ANALYSIS TOOL

BIOENGINEERING

CRISPR METHODS, AGRICULTURE/PLANTS

The Plant journal : for cell and molecular biology, Feb 2022

REMOVING THE MAJOR ALLERGEN BRA J I FROM BROWN MUSTARD (BRASSICA JUNCEA) BY
CRISPR/CAS9.

Assou J et al. Food allergies are a major health issue worldwide. Modern
breeding techniques such as genome editing via CRISPR/Cas9 have the potential to
mitigate this by targeting allergens in plants. This study addressed the major
allergen Bra j I, a seed storage protein of the 2S albumin class, in the
allotetra

ICE CRISPR ANALYSIS TOOL

BASIC RESEARCH, BIOENGINEERING

AGRICULTURE/PLANTS

Nature medicine, Feb 2022

HLA-INDEPENDENT T CELL RECEPTORS FOR TARGETING TUMORS WITH LOW ANTIGEN DENSITY.

Mansilla-Soto J et al. Chimeric antigen receptors (CARs) are receptors for
antigen that direct potent immune responses. Tumor escape associated with low
target antigen expression is emerging as one potential limitation of their
efficacy. Here we edit the TRAC locus in human peripheral blood T cells to
engage cell-surface

SYNTHETIC SGRNA

DISEASE MODELING/ RESEARCH

CANCER, IMMUNOLOGY

Plant biotechnology journal, Feb 2022

WI12RHG1 INTERACTS WITH DELLAS AND MEDIATES SOYBEAN CYST NEMATODE RESISTANCE
THROUGH HORMONE PATHWAYS.

Dong J et al. 

ICE CRISPR ANALYSIS TOOL

GENE FUNCTION

AGRICULTURE/PLANTS

Molecular & cellular proteomics : MCP, Jan 2022

TUNING DO:DM RATIOS MODULATES MHC CLASS II IMMUNOPEPTIDOMES.

Olsson N et al. Major histocompatibility complex class II (MHC-II) antigen
presentation underlies a wide range of immune responses in health and disease.
However, how MHC-II antigen presentation is regulated by the peptide-loading
catalyst HLA-DM (DM), its associated modulator, HLA-DO (DO), is incompletely
understo

SYNTHETIC SGRNA

BASIC RESEARCH, OTHER

IMMUNOLOGY, FUNDAMENTAL BIOLOGY

Scientific reports, Jan 2022

A CELL-BASED PHENOTYPIC LIBRARY SELECTION AND SCREENING APPROACH FOR THE DE NOVO
DISCOVERY OF NOVEL FUNCTIONAL CHIMERIC ANTIGEN RECEPTORS.

Fierle JK et al. Anti-tumor therapies that seek to exploit and redirect the
cytotoxic killing and effector potential of autologous or syngeneic T cells have
shown extraordinary promise and efficacy in certain clinical settings. Such
cells, when engineered to express synthetic chimeric antigen receptors (CARs)
acquir

KNOCKOUT CELL POOL

DRUG DISCOVERY

IMMUNOLOGY, OTHER METHODS

Cell, Jan 2022

ENGINEERED VIRUS-LIKE PARTICLES FOR EFFICIENT IN VIVO DELIVERY OF THERAPEUTIC
PROTEINS.

Banskota S et al. Methods to deliver gene editing agents in vivo as
ribonucleoproteins could offer safety advantages over nucleic acid delivery
approaches. We report the development and application of engineered DNA-free
virus-like particles (eVLPs) that efficiently package and deliver base editor or
Cas9 ribonucleop

ICE CRISPR ANALYSIS TOOL

DISEASE MODELING/ RESEARCH

CANCER

Cancer discovery, Jan 2022

SUBVERSION OF SEROTONIN-RECEPTOR SIGNALING IN OSTEOBLASTS BY KYNURENINE DRIVES
ACUTE MYELOID LEUKEMIA.

Galan-Diez M et al. Remodeling of the microenvironment by tumor cells can
activate pathways that favor cancer growth. Molecular delineation and targeting
of such malignant-cell non-autonomous pathways may help overcome resistance to
targeted-therapies. Herein we leverage genetic mouse models, patient-derived
xenografts

SYNTHETIC SGRNA

DISEASE MODELING/ RESEARCH

CANCER, IMMUNOLOGY

Molecular and cellular biology, Jan 2022

TARGETING PTPN22 DOES NOT ENHANCE THE EFFICACY OF CAR T CELLS IN SOLID TUMOURS.

Du X et al. Adoptive cell therapy with chimeric antigen receptor (CAR) T cells
has revolutionised the treatment of certain B cell malignancies, but has been in
ineffective against solid tumours. Recent studies have highlighted the potential
of targeting negative regulators of T cell signalling to enhance the ef

SYNTHETIC SGRNA

DISEASE MODELING/ RESEARCH

CANCER, IMMUNOLOGY

BMC biology, Jan 2022

STEM CELL-DERIVED PORCINE MACROPHAGES AS A NEW PLATFORM FOR STUDYING
HOST-PATHOGEN INTERACTIONS.

Meek S et al. Infectious diseases of farmed and wild animals pose a recurrent
threat to food security and human health. The macrophage, a key component of the
innate immune system, is the first line of defence against many infectious
agents and plays a major role in shaping the adaptive immune response. However,

SYNTHETIC SGRNA

OTHER

OTHER METHODS, INFECTIOUS DISEASE, LIVESTOCK

International journal of molecular sciences, Jan 2022

OPTIMIZATION OF PROTOPLAST ISOLATION AND TRANSFORMATION FOR A PILOT STUDY OF
GENOME EDITING IN PEANUT BY TARGETING THE ALLERGEN GENE ARA H 2.

Biswas S et al. The cultivated peanut (Arachis hypogaea L.) is a legume consumed
worldwide in the form of oil, nuts, peanut butter, and candy. Improving peanut
production and nutrition will require new technologies to enable novel trait
development. Clustered regularly interspaced short palindromic repeats and CRIS

SYNTHETIC SGRNA

OTHER

AGRICULTURE/PLANTS

Nature communications, Jan 2022

A BAFF LIGAND-BASED CAR-T CELL TARGETING THREE RECEPTORS AND MULTIPLE B CELL
CANCERS.

Wong DP et al. B cell-activating factor (BAFF) binds the three receptors BAFF-R,
BCMA, and TACI, predominantly expressed on mature B cells. Almost all B cell
cancers are reported to express at least one of these receptors. Here we develop
a BAFF ligand-based chimeric antigen receptor (CAR) and generate BAFF CAR-T

SYNTHETIC SGRNA

DISEASE MODELING/ RESEARCH

CANCER, IMMUNOLOGY, FUNDAMENTAL BIOLOGY

Nature communications, Jan 2022

CANONICAL WNT SIGNALING-DEPENDENT GATING OF MYC REQUIRES A NONCANONICAL CTCF
FUNCTION AT A DISTAL BINDING SITE.

Chachoua I et al. Abnormal WNT signaling increases MYC expression in colon
cancer cells in part via oncogenic super-enhancer-(OSE)-mediated gating of the
active MYC to the nuclear pore in a poorly understood process. We show here that
the principal tenet of the WNT-regulated MYC gating, facilitating nuclear export
of

SYNTHETIC SGRNA

DISEASE MODELING/ RESEARCH

CANCER, IMMUNOLOGY, FUNDAMENTAL BIOLOGY

Browse and Search All Publications  
Latest from the Bench
Use CRISPR10 min read


KARYOTYPING: DIFFERENT METHODS AND THEIR SIGNIFICANCE IN CELL-BASED RESEARCH

CRISPR Applications22 min read


PERSONALIZED MEDICINE FOR ADVANCED STAGE CANCER PATIENTS: BRYCE OLSON’S STORY

CRISPR Applications13 min read


CRISPR IN CANCER THERAPEUTICS: CAR-T, NK, TCR AND BEYOND

Visit the Bench Blog  
The Genome Engineering Experts


LEVERAGING MACHINE LEARNING, AUTOMATION, AND GENE EDITING TO BUILD PLATFORMS FOR
SCIENCE AT SCALE.

WE’VE PERFORMED

250,000+ Edits

AVERAGE EDITING EFFICIENCY

80%

SUPPORTING RESEARCH IN

45+ Countries

CITED IN

648 Publications

--------------------------------------------------------------------------------


ABOUT SYNTHEGO

We enable the acceleration of life science research and development in the
pursuit of improved human health.

Learn More



PARTNERSHIPS

We partner with both commercial and academic entities to develop genome
engineering technologies.

Learn More



NEWSROOM

Get in touch, check out news and press releases or download our brand resources.



Learn More


FULL STACK GENOME ENGINEERING

Products

ENGINEERED CELLS

KNOCKOUT IPS CELLS

KNOCK-IN IPS CELLS

IMMORTALIZED KNOCKOUT POOL

IMMORTALIZED KNOCKOUT CLONE

GET A QUOTE

CRISPR KITS

GENE KNOCKOUT KIT V2

SYNTHETIC SGRNA

GMP SGRNA

ADVANCED RNA

SCREENING LIBRARIES

Learning Center

CRISPR

METHODS

HOW TO GUIDE

STEM CELLS

PRIMARY CELLS

CANCER

SICKLE CELL

NEWS SOURCES

IPSCS

GENOME ENGINEERING

HISTORY

TECHNIQUES & APPLICATIONS

Resources

RESOURCE LIBRARY

THE BENCH BLOG

CRISPR CUTS PODCAST

HELP CENTER

EVENTS

Company

ABOUT SYNTHEGO

PLATFORMS

HALO

ECLIPSE

PARTNERSHIPS

CAREERS

NEWSROOM

CONTACT

COPYRIGHT © 2022 SYNTHEGOPRIVACY POLICYTERMS OF USETERMS OF SALEMONEY BACK
GUARANTEES

  Subscribe